RNA: Now that RNA's partnership with GSK is over and more importantly GSK is out of the decision-making process, I wouldn't be surprised if Sarepta (SRPT) buys them out for a decent premium, especially considering the current ridiculously low valuation.
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.